#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Crigler-Najjar syndrome Synovial sarcoma Chronic inflammatory demyelinating polyradiculoneuropathy Restless legs syndrome Congenital pseudarthrosis Congenital myopathy Still's disease Congenital generalised lipodystrophy Congenital disorder of glycosylation Diffuse large B-cell lymphoma recurrent Richter's syndrome Stiff person syndrome Adenomatous polyposis coli Anti-HLA antibody test positive Cervix carcinoma More trials…

    Learn about Rare Diseases

    Urea cycle disorder – Trials in Disease Pleural mesothelioma malignant – Diagnostics Isodicentric chromosome 15 syndrome – Treatment Netherton’s syndrome – Life with Disease Netherton’s syndrome Adrenogenital syndrome – Trials in Disease Glycogen storage disease type I – Basic Information Langerhans cell sarcoma – Life with Disease Malignant fibrous histiocytoma – Trials in Disease Wiskott-Aldrich syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    PEGVISOMANT Pentixafor Sacituzumab Govitecan INF904 Art6043 Pitolisant Sodium Thiosulfate Coffee Charcoal Gozetotide Alf-18 Iobitridol Eplontersen Rbp030.2 Garadacimab AMO959 Human Serum Albumin 5% Human Von Willebrand Factor Lenacapavir Sodium Tarlatamab M-(18F)-Fluorobenzylguanidine Abelacimab More therapies…

    Learn about Your Condition

    Death neonatal Cardiovascular disorder Inflammatory bowel disease Urinary tract infection Menopause Non-Hodgkin's lymphoma Bladder cancer recurrent Peripheral artery thrombosis Immunodeficiency congenital Diabetes insipidus Limb reduction defect Ewing's sarcoma Retinopathy proliferative Chronic lymphocytic leukaemia Thromboembolectomy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic lymphocytic leukaemia refractory

  • Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • B-cell small lymphocytic lymphoma
    France Hungary Italy Poland

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Follicular lymphoma stage II
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • BGB-16673
    • Mosunetuzumab
    Germany Italy Poland

  • Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

    Recruiting

    1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    Investigated Drugs:
    • Mb-Cart20.1
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    • Zamtocabtagene Autoleucel
    Germany

  • Study on PTG-CARCIK-CD19 for Adults and Children with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Recruiting

    1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia refractory
    Investigated Drugs:
    • Ptg-Carcik-Cd19
    Italy

  • Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • B-cell small lymphocytic lymphoma
    Investigated Drugs:
    • Venetoclax
    The Netherlands

  • Study on Ibrutinib and Venetoclax for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia refractory
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Venetoclax
    Italy
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!